Synopsys (SNPS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

28.05.25 23:30 Uhr

Werte in diesem Artikel
Aktien

76,00 EUR -2,00 EUR -2,56%

394,25 EUR 5,80 EUR 1,49%

Indizes

21.341,0 PKT -23,0 PKT -0,11%

19.113,8 PKT -62,1 PKT -0,32%

5.911,7 PKT -0,5 PKT -0,01%

For the quarter ended April 2025, Synopsys (SNPS) reported revenue of $1.6 billion, up 10.3% over the same period last year. EPS came in at $3.67, compared to $3.00 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.6 billion, representing a surprise of +0.16%. The company delivered an EPS surprise of +8.26%, with the consensus EPS estimate being $3.39.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Synopsys performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- Maintenance and service: $265.26 million versus $279.24 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -4.1% change. Revenue- Total products revenue: $1.34 billion compared to the $1.32 billion average estimate based on four analysts. The reported number represents a change of +13.7% year over year. Revenue by segment- Design IP: $482 million compared to the $443.37 million average estimate based on three analysts. The reported number represents a change of +20.6% year over year. Revenue by segment- Design Automation: $1.12 billion compared to the $1.16 billion average estimate based on three analysts. The reported number represents a change of +6.4% year over year. Revenue- Upfront products: $510.68 million versus the three-analyst average estimate of $415.15 million. The reported number represents a year-over-year change of +28.8%. Revenue- Time-based products: $828.33 million compared to the $904.12 million average estimate based on three analysts. The reported number represents a change of +6% year over year. View all Key Company Metrics for Synopsys here>>>Shares of Synopsys have returned +11.1% over the past month versus the Zacks S&P 500 composite's +7.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Synopsys, Inc. (SNPS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Q2 und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Q2

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Q2

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Synopsys Inc.

Wer­bung

Analysen zu Synopsys Inc.

DatumRatingAnalyst
22.08.2019Synopsys BuyNeedham & Company, LLC
03.04.2019Synopsys BuyNeedham & Company, LLC
28.03.2019Synopsys BuyNeedham & Company, LLC
06.12.2018Synopsys BuyNeedham & Company, LLC
06.12.2018Synopsys BuyThe Benchmark Company
DatumRatingAnalyst
22.08.2019Synopsys BuyNeedham & Company, LLC
03.04.2019Synopsys BuyNeedham & Company, LLC
28.03.2019Synopsys BuyNeedham & Company, LLC
06.12.2018Synopsys BuyNeedham & Company, LLC
06.12.2018Synopsys BuyThe Benchmark Company
DatumRatingAnalyst
09.09.2015Synopsys HoldThe Benchmark Company
04.12.2008Synopsys UpgradeCitigroup Corp.
02.02.2007Synopsys neutralDA Davidson
31.01.2007Update Synopsys Inc.: NeutralDA Davidson
30.11.2006Synopsys holdDeutsche Securities
DatumRatingAnalyst
21.08.2008Synopsys DowngradeCitigroup Corp.
24.06.2005Synopsys underweightPrudential Financial

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Synopsys Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen